This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roblin, P. M.
Right arrow Articles by Hammerschlag, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roblin, P. M.
Right arrow Articles by Hammerschlag, M. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 1998, p. 194-196, Vol. 42, No. 1
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Microbiologic Efficacy of Azithromycin and Susceptibilities to Azithromycin of Isolates of Chlamydia pneumoniae from Adults and Children with Community-Acquired Pneumonia

Patricia M. Roblin and Margaret R. Hammerschlag*

Departments of Pediatrics and Medicine, State University of New York Health Science Center at Brooklyn, Brooklyn, New York

Received 23 June 1997/Returned for modification 2 September 1997/Accepted 16 October 1997

Chlamydia pneumoniae was eradicated from the nasopharynges of 26 of 33 (78.8%) evaluable children and adults with community-acquired pneumonia who were treated with azithromycin. We tested 55 isolates of C. pneumoniae obtained from 46 of these patients against azithromycin. The MIC at which 90% of the isolates were inhibited and the minimal chlamydiacidal concentration at which 90% of strains tested were killed of azithromycin for these isolates were both 0.5 µg/ml. Seven patients remained culture positive after treatment. The MICs of azithromycin for isolates from two patients increased fourfold after therapy. However, all the patients with persistent infection improved clinically. Further studies of treatment of C. pneumoniae infection, utilizing culture, are needed both to assess efficacy and to monitor for the possible development of antibiotic resistance.

* Corresponding author. Mailing address: Department of Pediatrics, Box 49, SUNY Health Science Center at Brooklyn, 450 Clarkson Ave., Brooklyn, NY 11203-2098. Phone: (718) 245-4075. Fax: (718) 245-2118. E-mail: mhammerschlag{at}pol.net.

Antimicrobial Agents and Chemotherapy, January 1998, p. 194-196, Vol. 42, No. 1
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Baker, W. L., Couch, K. A. (2007). Azithromycin for the secondary prevention of coronary artery disease: A meta-analysis. Am J Health Syst Pharm 64: 830-836 [Abstract] [Full Text]  
  • Binet, R., Maurelli, A. T. (2005). Frequency of Spontaneous Mutations That Confer Antibiotic Resistance in Chlamydia spp.. Antimicrob. Agents Chemother. 49: 2865-2873 [Abstract] [Full Text]  
  • Pelton, S. I., Hammerschlag, M. R. (2005). Overcoming Current Obstacles in the Management of Bacterial Community-Acquired Pneumonia in Ambulatory Children. CLIN PEDIATR 44: 1-17  
  • Riska, P. F., Kutlin, A., Ajiboye, P., Cua, A., Roblin, P. M., Hammerschlag, M. R. (2004). Genetic and Culture-Based Approaches for Detecting Macrolide Resistance in Chlamydia pneumoniae. Antimicrob. Agents Chemother. 48: 3586-3590 [Abstract] [Full Text]  
  • Miyashita, N., Fukano, H., Yoshida, K., Niki, Y., Matsushima, T. (2003). In vitro activity of cethromycin, a novel antibacterial ketolide, against Chlamydia pneumoniae. J Antimicrob Chemother 52: 497-499 [Abstract] [Full Text]  
  • Yamaguchi, H., Friedman, H., Yamamoto, M., Yasuda, K., Yamamoto, Y. (2003). Chlamydia pneumoniae Resists Antibiotics in Lymphocytes. Antimicrob. Agents Chemother. 47: 1972-1975 [Abstract] [Full Text]  
  • Ewig, S., Torres, A. (2003). Is Chlamydia pneumoniae an important pathogen in patients with community-acquired pneumonia?. Eur Respir J 21: 741-742 [Full Text]  
  • Hammerschlag, M. R., Reznik, T., Roblin, P. M., Ramirez, J., Summersgill, J., Bukofzer, S. (2003). Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. J Antimicrob Chemother 51: 1025-1028 [Abstract] [Full Text]  
  • Miyashita, N., Fukano, H., Yoshida, K., Niki, Y., Matsushima, T. (2003). Chlamydia pneumoniae infection in adult patients with persistent cough. J Med Microbiol 52: 265-269 [Abstract] [Full Text]  
  • Paladino, J. A., Gudgel, L. D., Forrest, A., Niederman, M. S. (2002). Cost-Effectiveness of IV-to-Oral Switch Therapy: Azithromycin vs Cefuroxime With or Without Erythromycin for the Treatment of Community-Acquired Pneumonia. Chest 122: 1271-1279 [Abstract] [Full Text]  
  • Morrissey, I., Salman, H., Bakker, S., Farrell, D., Bebear, C. M., Ridgway, G. (2002). Serial passage of Chlamydia spp. in sub-inhibitory fluoroquinolone concentrations. J Antimicrob Chemother 49: 757-761 [Abstract] [Full Text]  
  • Kutlin, A., Roblin, P. M., Hammerschlag, M. R. (2002). Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model. J Antimicrob Chemother 49: 763-767 [Abstract] [Full Text]  
  • Kutlin, A., Roblin, P. M., Hammerschlag, M. R. (2002). Effect of Prolonged Treatment with Azithromycin, Clarithromycin, or Levofloxacin on Chlamydia pneumoniae in a Continuous-Infection Model. Antimicrob. Agents Chemother. 46: 409-412 [Abstract] [Full Text]  
  • Malay, S., Roblin, P. M., Reznik, T., Kutlin, A., Hammerschlag, M. R. (2002). In Vitro Activities of BMS-284756 against Chlamydia trachomatis and Recent Clinical Isolates of Chlamydia pneumoniae. Antimicrob. Agents Chemother. 46: 517-518 [Abstract] [Full Text]  
  • Boman, J., Hammerschlag, M. R. (2002). Chlamydia pneumoniae and Atherosclerosis: Critical Assessment of Diagnostic Methods and Relevance to Treatment Studies. Clin. Microbiol. Rev. 15: 1-20 [Abstract] [Full Text]  
  • Hammerschlag, M. R., Roblin, P. M. (2000). Microbiological Efficacy of Levofloxacin for Treatment of Community-Acquired Pneumonia Due to Chlamydia pneumoniae. Antimicrob. Agents Chemother. 44: 1409-1409 [Full Text]  
  • Cook, P. J. (1999). Antimicrobial therapy for Chlamydia pneumoniae: its potential role in atherosclerosis and asthma. J Antimicrob Chemother 44: 145-148 [Full Text]  
  • Freidank, H. M., Losch, P., Vögele, H., Wiedmann-Al-Ahmad, M. (1999). In Vitro Susceptibilities of Chlamydia pneumoniae Isolates from German Patients and Synergistic Activity of Antibiotic Combinations. Antimicrob. Agents Chemother. 43: 1808-1810 [Abstract] [Full Text]  
  • Wolf, K., Malinverni, R. (1999). Effect of Azithromycin plus Rifampin versus That of Azithromycin Alone on the Eradication of Chlamydia pneumoniae from Lung Tissue in Experimental Pneumonitis. Antimicrob. Agents Chemother. 43: 1491-1493 [Abstract] [Full Text]  
  • Gieffers, J., Solbach, W., Maass, M. (1998). In Vitro Susceptibilities of Chlamydia pneumoniae Strains Recovered from Atherosclerotic Coronary Arteries. Antimicrob. Agents Chemother. 42: 2762-2764 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»